DGS Capital Management LLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

DGS Capital Management LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 40,795 shares of the company’s stock after selling 1,208 shares during the period. Novo Nordisk A/S comprises about 0.9% of DGS Capital Management LLC’s portfolio, making the stock its 17th largest holding. DGS Capital Management LLC’s holdings in Novo Nordisk A/S were worth $3,509,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Raymond James & Associates grew its position in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after buying an additional 36,223 shares during the period. Natixis Advisors LLC raised its position in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. LPL Financial LLC grew its position in shares of Novo Nordisk A/S by 3.6% during the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after acquiring an additional 47,496 shares during the period. Finally, Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NVO stock opened at $87.94 on Friday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s fifty day moving average is $95.62 and its two-hundred day moving average is $115.55. The firm has a market capitalization of $394.65 billion, a P/E ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.